Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-01-27
2001-10-16
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S024000, C514S152000, C514S199000, C514S200000, C514S394000
Reexamination Certificate
active
06303644
ABSTRACT:
FIELD OF APPLICATION OF THE INVENTION
The invention relates to the use of proton pump inhibitors as combination therapeutics in the treatment of bacterial diseases which do not affect the gastrointestinal tract using antibacterially active compounds.
KNOWN TECHNICAL BACKGROUND
A large number of patent applications and patents describe variously substituted 2-(2-pyridinylmethylsulfinyl)-1H-benzimidazoles, This class of compound is able to specifically inhibit gastric acid production and is therefore also described as the proton pump Inhibitors class. A whole series of proton pump inhibitors are in an advanced stage of clinical testing or already on the market. The following compounds, designated by the INN, which may be mentioned as examples are: omeprazole (EP-B 005 129), pantoprazole (EP-B 168 287), lansoprazole (EP-B 174 726), rabeprazole (EP-B 268 956), lemninoprazole (DE-A 35 31 487) and nepaprazole (EP-A 434 999).
European Patent 166 287, in which, inter alia, the compound pantoprazole (INN) is patented, states that the compounds according to the invention are suitable for the prevention and treatment of gastrointestinal diseases, such as can be caused, for example, by microorganisms, bacterial toxins, antiinflammatories, antirheumatics, ethanol, gastric acid or stress situations.—European Patent 544 760 describes combinations of pantoprazole with antibacterially active compounds for controlling the bacterium Helicobacter pylori, which populates the stomach.
REFERENCES:
patent: 5629305 (1997-05-01), Eek et al.
patent: 5945124 (1999-08-01), Sachs et al.
patent: 6134344 (2000-10-01), Depui et al.
patent: 35 31 487 (1986-03-01), None
patent: 0 005 129 (1979-10-01), None
patent: 0 166 287 (1986-01-01), None
patent: 0 174 726 (1986-03-01), None
patent: 0 268 956 (1988-06-01), None
patent: 0 434 999 (1991-07-01), None
patent: 0 544 760 (1993-06-01), None
patent: 92/03135 (1992-03-01), None
patent: 93/12817 (1993-07-01), None
patent: 94/07490 (1994-04-01), None
patent: 97/02021 (1997-01-01), None
Windholz et al., The Merck Index., Tenth Edition, (1983) p. 83, reference No. 600 (amoxicillin).*
Hirai et al., “A Proton Pump Inhibitor, E3810, Has Antibacterial Activity Through Binding to Helicobacter Pylori”, Journal of Gastroenterology, 1995; 30:461-464.
Murakami et al., “Atopic Dermatitis Successfully Treated by Eradication of Helicobacter Pylori”, J Gastroenterol, Nov. 1996, 31 Suppl 9 P77-82.
Jonkers et al., “Omeprazole Inhibits Growth of Gram-Positive and Gram-Negative Bacteria Including Helicobacter Pylori in Vitro”, J Antimicrob Chemother, Jan 1996, 37 (1), P145-50.
Greco et al., “Glossitis, Stomatitis, and Black Tongue With Lansoprazole Plus Clarithromycin and Other Antibiotics (1)” Annals of Pharmacotherapy, 1997, 31/12, (1548).
Kalas et al., “Connection Between Helicobacter Pylori Infection and Chronic Gastrointestinal Urticarial”, Orv Hetil, Sep. 8, 1996, 137 (36), P1969-72.
Reinauer et al., “Schonlein-Henoch Purpura Associated With Gastric Helicobacter Pylori Infection”, J Am Acad Dermatol, 11/95, 33 (5 PT 2) P876-9.
Malfertheiner, “Current European Concepts in the Management of Helicobacter Pylori Infection. The Maastricht Concensus Report”, Gut, 1997, 41/1 (8-13).
Sachs, “Proton Pump Inhibitors and Acid-Related Diseases”, Pharmacotherapy, 1997, 17/1 (22-37).
Kuipers et al., “Athrophic Gastritis and Helicobacter Pylori Infection in Patients with Reflux Esophagitis Treated With Omeprazole or Fundoaplication”, New England Journal of Medicine, BD. 334, NR. 16, Apr. 18, 1996.
ByK Gulden Lomberg Chemische Fabrik GmbH
Jacobson & Holman PLLC
Weddington Kevin E.
LandOfFree
Proton pump inhibitor in therapeutic combination with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proton pump inhibitor in therapeutic combination with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proton pump inhibitor in therapeutic combination with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2581747